J&J R&D role next up for John Reed

14 February 2023
johnson_big

Following the announcement yesterday that Sanofi’s (Euronext: SAN) global head of R&D John Reed is leaving the French drugmaker, his destination has been revealed as the US healthcare giant Johnson & Johnson (NYSE: JNJ).

Dr Reed joins the group’s executive committee as executive vice president of Pharmaceuticals, R&D, assuming responsibility for the company’s portfolio. He will start his new role on April 3, taking over from William Hait, who had been interim head of J&J’s Pharmaceutical R&D organization since August 2022.

"An extraordinary track record for discovering and developing life-saving innovations"

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical